Long-Term Follow-Up of Patients Immunized with AN1792 Current Alzheimer Research, 2009, Vol. 6, No. 2 151 Mark Brody, Brain Matters Research, Inc., Delray Beach, FL. Jody Corey-Bloom, Alzheimer’s Disease Research Center, UCSD, La Jolla, CA. Mercè Boada Rovira, Fundació ACE, Institut Català de Neu- rociències Aplicades, Barcelona, Spain. Jean-Francois Dartigues, Hôpital Pellegrin–Tripode, Bor- deaux, France. Rachelle Doody, Baylor College of Medicine, Houston, TX. Bruno Dubois, Hôpital La Pitié Salpêtrière, Paris, France. Stephen Flitman, Xenoscience Inc., Phoenix, AZ. Ana Frank-Garcia, Hospital Universitario La Paz, Madrid, Spain. Daniel Grosz, Pharmacology Research Institute, Northridge, CA. Christoph Hock, University of Zurich, Zurich, Switzerland. Pierre Jouanny, Hôtel Dieu–CHU, Rennes, France. Louis Kirby, Pivotal Research Centers, Peoria, AZ. David Knopman, Mayo Clinic, Rochester, MN. Bernard Laurent, Hôpital Bellevue, Saint-Etienne, France. Michel, Hôpital Sainte-Marguerite, Marseille, Bernard France. José Luis Molinuevo, Institut d’Investigació Biomèdica August Pi i Sunyer, Barcelona, Spain. Florence Pasquier, Hôpital Roger Salengro, Lille, France. Jordi Pena-Casanova, Hospital del Mar, Barcelona, Spain. José Ribera Casado, Hospital Clinico, San Carlos, Madrid, Spain. Ralph Richter, Clinical Pharmaceutical Trials, Inc., Tulsa, OK. Anne-Sophie Rigaud, Broca Hospital, Paris, France. Jacques Touchon, Hôpital Gui de Chaulliac, Montpellier, France. Bruno Vellas, CHU La Grave–Casselardit, Toulouse, France. REFERENCES [1] Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Fore- casting the global burden of Alzheimer’s disease. Alzheimer De- ment 3: 186-191 (2007). Received: March 04, 2008 Revised: May 19, 2008 Accepted: May 23, 2008 [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid- attenuates Alzheimer-disease- like pathology in the PDAPP mouse. Nature 400: 173-177 (1999). Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F -amyloid precursor protein. Nature 373: 523-527 (1995). Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey G, Hardy J, et al. A peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 408: 982-985 (2000). Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schimdt SD, et al. A peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer’s disease. Nature 408: 979- 982 (2000). McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8: 1263-1269 (2002). Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jen- kins L, et al. Evaluation of the safety and immunogenicity of syn- thetic Abeta42 (AN1792) in patients with AD. Neurology 64: 94- 101 (2005). Orgogozo J-M, Gilman S, Dartigues J-F, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after A 42 immunization. Neurology 61: 46-54 (2003). Gilman S, Killer M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of A immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1563-1572 (2005). Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, et al. Effects of A immunization (AN1792) on MRI measures of cerebral volume in Alzheimer’s disease. Neurology 64: 1553-1562 (2005). Ferrer I, Boada RM, Sanchez Guerra ML, Rossor MN, Griffith SG, Jenkins L, et al. Neuropathology and pathogenesis of encephalitis following amyloid- immunization in Alzheimer’s disease. Brain Pathol 14: 11-20 (2004). Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, et al. A vaccination effects on plaque pathology in the absence of encepha- litis in Alzheimer’s disease. Neurology 64: 129-131 (2005). Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H and Weller RO. Neuropathology of human Alzheimer’s disease after immunization with amyloid- peptide: a case report. Nat Med 9: 448-452 (2003). Gauthier S, Gelinas I and Gauthier L. Functional disability in Alz- heimer’s disease. Int Psychogeriatr 9(suppl 1): 163-165 (1997). Stern Y, Albert SM, Sano M, Jacobs DM, Tang MX, Marder K, et al. Assessing patient dependence in Alzheimer’s disease. J Geron- tol 49: M216-222 (1994). Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43: 2412-2414 (1993). Harrison J, Minassian SL, Jenkins L, Black RS, Koller M and Grundman M. A neuropsychological test battery for use in Alz- heimer’s disease clinical trials. Arch Neurol 64: 1323-1329 (2007). Folstein MF, Folstein SE and McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198 (1975). Rosen WG, Mohs RC and Davis KL. A new rating scale for Alz- heimer’s disease. Am J Psychiatry 141: 1356-1364 (1984).